Association Between Copeptin and Six-Month Neurologic Outcomes in Patients With Moderate Traumatic Brain Injury

Frontiers in Neurology

Jeong Jin Park¹  Suk Hyung Kang²  Jin Pyeong Jeon²  Jun Hyong Ahn²  Jong Kook Rhim³  Seonghyeon Kim⁴  Heung Cheol Kim⁵  Dong Hyuk Youn⁶  Chan Hum Park⁶  Jong-Tae Kim⁶  Sung Woo Han⁶  Seung Hyuk Lim⁶  Bong Jun Kim⁶  Eun Pyo Hong⁶  Tae Yeon Kim⁶ 

[1] Department of Neurology, Konkuk Medical Center, Seoul, South Korea;Department of Neurosurgery, Hallym University College of Medicine, Chuncheon, South Korea;Department of Neurosurgery, Jeju National University College of Medicine, Jeju, South Korea;Department of Orthopaedic Surgery, Hallym University College of Medicine, Chuncheon, South Korea;Department of Radioilogy, Hallym University College of Medicine, Chuncheon, South Korea;Institute of New Frontier Research, Hallym University College of Medicine, Chuncheon, South Korea;

关键词: biomarkers;    traumatic brain injury;    copeptin;    outcome;    cohort study;   

DOI  :  10.3389/fneur.2021.749110

来源: DOAJ

【 摘 要 】

BackgroundCopeptin has been reported as a predictive biomarker for the prognosis after traumatic brain injury (TBI). However, most of them were in patients with severe TBI and limited value in predicting outcomes in patients with moderate TBI defined as Glasgow Coma Scale (GCS) score from 9 to 12. We aimed to investigate the predictive value of copeptin in assessing the neurologic outcome following moderate TBI.MethodsPatients were prospectively enrolled between May 2017 and November 2020. We consecutively measured plasma copeptin within 24 h after trauma, days 3, 5, and 7 using ELISA. The primary outcome was to correlate plasma copeptin levels with poor neurologic outcome at 6 months after moderate TBI. The secondary outcome was to compare the prognostic accuracy of copeptin and C-reactive protein (CRP) in assessing the outcome of patient.ResultsA total of 70 patients were included for the final analysis. The results showed that 29 patients (41.4%) experienced a poor neurologic outcome at 6 months. Multivariable logistic regression analysis revealed that increased copeptin (odds ration [OR] = 1.020, 95% CI: 1.005–1.036), GCS score of 9 or 10 (OR = 4.507, 95% CI: 1.266–16.047), and significant abnormal findings on CT (OR = 4.770; 95% CI: 1.133–20.076) were independent risk factors for poor outcomes. Consecutive plasma copeptin levels were significantly different according to outcomes (p < 0.001). Copeptin on day 7 exhibited better prognostic performance than CRP with an area under receiver operating characteristic curve (AUROC) difference of 0.179 (95% CI: 0.032–0.325) in predicting 6-month poor outcomes.ConclusionPlasma copeptin level can be a useful marker in predicting 6-month outcomes in patients with moderate TBI.

【 授权许可】

Unknown